Free Trial
NASDAQ:RLAY

Relay Therapeutics (RLAY) Stock Price, News & Analysis

$7.14
-0.12 (-1.65%)
(As of 08/27/2024 ET)
Today's Range
$7.00
$7.31
50-Day Range
$6.26
$9.48
52-Week Range
$5.70
$12.14
Volume
425,178 shs
Average Volume
1.19 million shs
Market Capitalization
$947.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.67

Relay Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
203.5% Upside
$21.67 Price Target
Short Interest
Bearish
6.82% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.84mentions of Relay Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$988,396 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.91) to ($3.07) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.48 out of 5 stars

Medical Sector

474th out of 921 stocks

Biological Products, Except Diagnostic Industry

72nd out of 142 stocks

RLAY stock logo

About Relay Therapeutics Stock (NASDAQ:RLAY)

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

RLAY Stock Price History

RLAY Stock News Headlines

Forget the Polls, Here’s What Will Happen this Election
According to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move…
Relay Therapeutics: A 'Concept' Stock
Forget the Polls, Here’s What Will Happen this Election
According to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move…
See More Headlines
Receive RLAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/06/2024
Today
8/27/2024
Next Earnings (Estimated)
11/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RLAY
Fax
N/A
Employees
330
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.67
High Stock Price Target
$30.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+203.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-341,970,000.00
Pretax Margin
-916.89%

Debt

Sales & Book Value

Annual Sales
$35.21 million
Book Value
$5.90 per share

Miscellaneous

Free Float
127,008,000
Market Cap
$947.78 million
Optionable
Optionable
Beta
1.66
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives


RLAY Stock Analysis - Frequently Asked Questions

How have RLAY shares performed this year?

Relay Therapeutics' stock was trading at $11.01 at the start of the year. Since then, RLAY shares have decreased by 35.1% and is now trading at $7.14.
View the best growth stocks for 2024 here
.

How were Relay Therapeutics' earnings last quarter?

Relay Therapeutics, Inc. (NASDAQ:RLAY) posted its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.04.

When did Relay Therapeutics IPO?

Relay Therapeutics (RLAY) raised $250 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO.

Who are Relay Therapeutics' major shareholders?

Relay Therapeutics' top institutional investors include Dimensional Fund Advisors LP (1.15%), Logos Global Management LP (0.98%), Millennium Management LLC (0.86%) and Renaissance Technologies LLC (0.68%). Insiders that own company stock include Mark Murcko, Sanjiv Patel, Donald A Bergstrom, Peter Rahmer, Thomas Catinazzo, Brian Adams and Andy Porter.
View institutional ownership trends
.

How do I buy shares of Relay Therapeutics?

Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Relay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG) and DraftKings (DKNG).

This page (NASDAQ:RLAY) was last updated on 8/28/2024 by MarketBeat.com Staff

From Our Partners